Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention : a cost-benefit analysis in the working-age population
Lazaro-Hernandez, Carlos (Hospital Universitari Vall d'Hebron)
Caronna, Edoardo (Vall d'Hebron Institut de Recerca (VHIR))
Rosell-Mirmi, Joana (Vall d'Hebron Institut de Recerca (VHIR))
Gallardo López, Victor José (Vall d'Hebron Institut de Recerca (VHIR))
Alpuente, Alicia (Vall d'Hebron Institut de Recerca (VHIR))
Torres-Ferrús, Marta (Vall d'Hebron Institut de Recerca (VHIR))
Pozo-Rosich, Patricia (Universitat Autònoma de Barcelona. Departament de Medicina)

Data:	2024
Resum:	Migraine is one of the main causes of disability worldwide. Anti-CGRP monoclonal antibodies (MAbs) have proven to be safe and efficacious as preventive migraine treatments. However, their use is restricted in many countries due to their apparently high cost. Cost-benefit studies are needed. To study the cost-benefit of anti-CGRP MAbs in working-age patients with migraine. This is a prospective cohort study of consecutive migraine patients treated with anti-CGRP MAbs (erenumab, fremanezumab and galcanezumab) following National reimbursement policy in a specialized headache clinic. Migraine characteristics and the work impact scale (WPAI) were compared between baseline (M0) and after 3 (M3) and 6 months (M6) of treatment. Using WPAI and the municipal average hourly wage, we calculated indirect costs (absenteeism and presenteeism) at each time point. Direct costs (emergency visits, acute medication use) were also analysed. A cost-benefit study was performed considering the different costs and savings of treating with MAbs. Based on these data an annual projection was conducted. From 256 treated working-age patients, 148 were employed (89. 2% women; mean age 48. 0 ± 8. 5 years), of which 41. 2% (61/148) were responders (.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Journal of headache and pain, Vol. 25 Núm. 1 (February 2024) , ISSN 1129-2377

DOI: 10.1186/s10194-024-01727-0
PMID: 38347485

9 p, 1013.7 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats